Back to "For MACE, no drug showed a significant e..."
Claim
Strong Support
causal
Analysis v3

In adults with heart failure, none of the GLP-1 receptor agonist drugs have been shown to lower the rate of serious heart-related events like heart attack or stroke compared to a placebo, even though...

52
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

In heart failure, the heart and blood vessels are already damaged in ways that block the protective signals from GLP-1 drugs. Even the strongest GLP-1 drugs cannot fix the underlying metabolic chaos, inflammation, and stress signals that drive heart attacks and strokes in these patients.

Most probable mechanism

In Simple Terms

In people with heart failure, the signals from GLP-1 receptors do not change how the heart handles stress or repairs itself, so the risk of serious heart problems like heart attacks or strokes stays the same even when these drugs are used.

Causal chain
1

GLP-1 receptors on cardiac myocytes and vascular endothelial cells are activated by agonists, but downstream signaling pathways involving cAMP/PKA and PI3K/Akt remain unaltered in the presence of heart failure-induced metabolic and inflammatory remodeling

Supported by evidence
which leads to
2

Cardiac energy metabolism shifts toward fatty acid dependence and mitochondrial dysfunction persist despite GLP-1 receptor stimulation, preventing improved myocardial efficiency

Supported by evidence
which leads to
3

Inflammatory cytokine networks and oxidative stress in the myocardium are not suppressed by GLP-1 receptor activation, maintaining endothelial dysfunction and plaque instability

Supported by evidence
which leads to
4

Neurohormonal activation, including sustained sympathetic tone and renin-angiotensin-aldosterone system activity, overrides any transient beneficial effects of GLP-1 receptor signaling on heart rate and blood pressure

Supported by evidence

Evidence from Studies

Supporting (1)

52

Community contributions welcome

52

Abstract 4368175: GLP-1 Analogues and Cardiovascular Outcomes in Heart Failure Patients: A Network Meta-Analysis

Systematic Review With Meta-Analysis
Human

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Abstract 4368175: GLP-1 Analogues and Cardiovascular Outcomes in Heart Failure Patients: A Network Meta-Analysis

Score: 52
DOI: 10.1161/circ.152.suppl_3.4368175

Similar Assertions

Some diabetes drugs like liraglutide, semaglutide, and dulaglutide may help protect the heart and lower the chance of serious heart problems in people with type 2 diabetes who already have heart disease — and this benefit might not just be because they lower blood sugar.

1
0
83%

If you're an overweight or obese adult without diabetes, taking GLP-1 drugs like Ozempic might lower your chances of having a heart attack by about 27% compared to taking a fake pill.

65
0
83%

In adults who are overweight or obese but do not have diabetes, medications that activate GLP-1 receptors lower the likelihood of heart attacks, strokes, and other serious heart-related events compared to a placebo.

39
0
80%

In adults with heart failure, tirzepatide lowers the chance of being hospitalized for heart failure by 53% compared to a placebo.

52
0
79%

In adults with heart failure, semaglutide and liraglutide lower the risk of death from cardiovascular causes, while tirzepatide and exenatide do not lower this risk.

52
0
78%